Why the study?
Does dual antiplatelet therapy (aspirin and clopidogrel) prevent ischemic stroke in patients with recent TIA or severe intracranial stenosis compared to aspirin alone?
Does dual antiplatelet therapy (aspirin and clopidogrel) prevent ischemic stroke in patients with recent TIA or severe intracranial stenosis compared to aspirin alone?
A 90-day course of dual antiplatelet therapy (aspirin and clopidogrel) may be beneficial for secondary stroke prophylaxis in patients with recent TIA or severe intracranial stenosis.
Dual antiplatelet therapy may benefit select recent TIA or severe intracranial stenosis patients short-term; leaves open need for confirmatory trials before wider use.
Ischemic stroke is defined as a sudden loss of blood to the brain which results in deprivation of oxygen and other nutrients. It can be either a transient episode called as "transient ischemic attack" (TIA), or it could last longer than 24 hours giving rise to "infarction of tissues" in the central nervous system. Anti-platelet agents are widely used for the secondary prophylaxis of ischemic stroke, and amongst them, aspirin remains the drug of choice. In this literature review, we summarized the existing data regarding the ischemic type of strokes with particular attention to the use of antiplatelet agents for this purpose. The following review highlights the significance of the use of dual antiplatelet (aspirin and clopidogrel) regimen for the stroke prevention. The role of dual antiplatelet (aspirin and clopidogrel) in patients with a recent TIA (within 30 days) or severe stenosis (70%-99%) of a major intracranial artery, for 90 days, might be a beneficial approach.
No takes yet. Share an insight, caveat, or question.
Anjum et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: